I am a professor at the University of Granada and Director of the research group consolidated by the Ministry of Education of the Junta de Andalucía, CTS-101: Intercell Communication. I am a supervisor of radioactive installations as well as a member of the CIBER of Fragility and Healthy Aging (CIBERfes). I am also a specialist in clinical biochemistry. I have developed my research for the last 25 years in the Department of Physiology of the Faculty of Medicine at the University of Granada, where I studied the antioxidant effects of melatonin and the identification of mitochondria as the main target of melatonin. Recently, my activity has focused on studies of the oncostatic activity of melatonin and on the adverse effects of radio- and chemotherapy. I have published more than 200 articles. We have obtained four international patents on melatonin in the last five years. I am part of the Cost MitoEagle action (EU-OC-2015-2-19984) of the CIBERFES (CB/10/00238).
I am a professor at the University of Granada and Director of the research group consolidated by the Ministry of Education of the Junta de Andalucía, CTS-101: Intercell Communication. I am a supervisor of radioactive installations as well as a member of the CIBER of Fragility and Healthy Aging (CIBERfes). I am also a specialist in clinical biochemistry. I have developed my research for the last 25 years in the Department of Physiology of the Faculty of Medicine at the University of Granada, where I studied the antioxidant effects of melatonin and the identification of mitochondria as the main target of melatonin. Recently, my activity has focused on studies of the oncostatic activity of melatonin and on the adverse effects of radio- and chemotherapy. I have published more than 200 articles. We have obtained four international patents on melatonin in the last five years. I am part of the Cost MitoEagle action (EU-OC-2015-2-19984) of the CIBERFES (CB/10/00238).